Ocera Therapeutics (TZYM) and Its Rivals Critical Survey

Ocera Therapeutics (NASDAQ: TZYM) is one of 50 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it compare to its rivals? We will compare Ocera Therapeutics to similar companies based on the strength of its valuation, institutional ownership, profitability, earnings, risk, analyst recommendations and dividends.

Earnings and Valuation

This table compares Ocera Therapeutics and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Ocera Therapeutics N/A N/A -1.63
Ocera Therapeutics Competitors $585.03 million $106.82 million 55.09

Ocera Therapeutics’ rivals have higher revenue and earnings than Ocera Therapeutics. Ocera Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Ocera Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocera Therapeutics N/A -215.86% -101.91%
Ocera Therapeutics Competitors -13,514.61% -103.41% -26.54%

Volatility & Risk

Ocera Therapeutics has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Comparatively, Ocera Therapeutics’ rivals have a beta of 1.21, suggesting that their average share price is 21% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Ocera Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocera Therapeutics 0 0 0 0 N/A
Ocera Therapeutics Competitors 129 800 1742 59 2.63

As a group, “Biopharmaceuticals” companies have a potential upside of 13.54%. Given Ocera Therapeutics’ rivals higher possible upside, analysts plainly believe Ocera Therapeutics has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

45.8% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 16.5% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ocera Therapeutics rivals beat Ocera Therapeutics on 6 of the 8 factors compared.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Receive News & Ratings for Ocera Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply